Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.12% | 21.84% | 24.72% | 30.37% | 22.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.12% | 21.84% | 24.72% | 30.37% | 22.57% |
| Cost of Revenue | 63.21% | 33.49% | 32.33% | 27.34% | 12.77% |
| Gross Profit | -13.83% | 17.23% | 21.34% | 31.99% | 27.90% |
| SG&A Expenses | 13.74% | 37.87% | 14.74% | 9.11% | 0.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.88% | 36.12% | 22.29% | 16.67% | 4.94% |
| Operating Income | -77.49% | -12.84% | 30.88% | 100.95% | 254.55% |
| Income Before Tax | -57.39% | -17.96% | 64.62% | -18.91% | 133.40% |
| Income Tax Expenses | 176.40% | 17.82% | 86.15% | 28.74% | 66.67% |
| Earnings from Continuing Operations | -81.80% | -30.20% | 56.20% | -31.94% | 156.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.80% | -30.20% | 56.20% | -31.94% | 156.66% |
| EBIT | -77.49% | -12.84% | 30.88% | 100.95% | 254.55% |
| EBITDA | -71.93% | -11.47% | 30.40% | 97.20% | 221.33% |
| EPS Basic | -81.79% | -31.31% | 51.26% | -34.10% | 155.13% |
| Normalized Basic EPS | -64.38% | -10.73% | 29.49% | 96.07% | 223.26% |
| EPS Diluted | -81.14% | -30.74% | 51.22% | -33.68% | 153.16% |
| Normalized Diluted EPS | -64.04% | -9.81% | 29.62% | 95.28% | 211.41% |
| Average Basic Shares Outstanding | -0.10% | 1.63% | 3.27% | 3.28% | 2.78% |
| Average Diluted Shares Outstanding | -1.06% | 0.59% | 3.17% | 3.69% | 6.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |